News & Videos - UCB - Page 2

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis PR Newswire ATLANTA, Sept. 23, 2024 With three new indications, BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases Approval in active PsA is supported by two Phase 3 studies in which BIMZELX showed...

UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper") PR Newswire ATLANTA, Aug. 16, 2024 The inaugural UCB Hidradenitis Suppurativa (HS) Summit will bring people living with HS, caregivers, advocacy leaders, and invited healthcare providers together on UCB's Atlanta campus to advance understanding of the HS treatment journey and unmet needs The UCB HS Summit will amplify the Make HStory...

UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire ATLANTA, July 29, 2024 Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the full cast for the world premiere musical It's All Your Fault, Tyler Price ! Music and lyrics by Ben Decter, book by Ben Decter and Kristin Hanggi , directed by Kristin Hanggi Performances begin November 7, 2024...

FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire ATLANTA, June 24, 2024 FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 Data showed a clinically significant reduction in generalized tonic-clonic seizures ( GTCS )...

New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire ATLANTA, June 13, 2024 Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can maintain their dosing regimen throughout pregnancy An in vitro study found that rheumatoid factor (RF) antibodies bind to Fc-containing tumor necrosis factor inhibitors (TNFis) but are not able to bind to...

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire ATLANTA, June 12, 2024 Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated with BIMZELX showed sustained and consistent clinical and patient-reported outcomes up to two years Late-breaking data revealed that >90 percent of patients with AS treated with BIMZELX showed no spinal...

La biofarmacéutica internacional UCB cumple 50 años en España y lo ha celebrado en el Colegio Oficial de Arquitectos de ......

El consejero de Justicia, Administración Local y Función Pública, José Antonio Nieto, espera que el protocolo sobre climatización ......

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa PR Newswire ATLANTA, May 23, 2024 BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX ® (bimekizumab-bkzx), in the treatment of adult patients with moderate-to-severe hidradenitis suppurativa ATLANTA , May 23, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today...

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire ATLANTA, April 12, 2024 Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyses for UCB's generalized myasthenia gravis (gMG) treatments, including post hoc and open-label extension results from the pivotal Phase 3 MycarinG study and additional Interim Analyses of RAISE-XT for the...

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire ATLANTA, April 10, 2024 Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach people of all ages, races, and genders, including those most impacted by HS Co-created with people living with HS and dermatologists, the educational campaign features a broad range of tailored...

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire ATLANTA, April 4, 2024 Application in moderate-to-severe hidradenitis suppurativa based on results from two Phase 3 studies where BIMZELX ® (bimekizumab-bkzx) showed clinically meaningful improvements vs. placebo at Week 16 which were sustained to Week 48 Application for the additional BIMZELX 2mL device...

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis PR Newswire ATLANTA, March 9, 2024 Late-breaking platform presentation showed that BIMZELX ® (bimekizumab-bkzx) rapidly achieved and maintained high rates of clinical and health-related quality-of-life responses through four years; six out of ten patients achieved complete skin clearance at Year 4 Responder-analyses demonstrated that...

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count PR Newswire ATLANTA, March 8, 2024 Patients treated with BIMZELX ® (bimekizumab-bkzx) demonstrated clinically meaningful improvements in skin pain up to 48 weeks, across various assessed outcomes At Week 16, patients treated with BIMZELX demonstrated greater draining tunnel reductions versus placebo that were sustained or improved to Week 48...

UCB on Growth Path for a Decade Plus PR Newswire BRUSSELS, Feb. 28, 2024 Revenue in 2023 reached € 5.25 billion (-5%; -6% CER 1 ), net sales were € 4.87 billion (-5%; -6% CER 1 ) – in-line with financial guidance Strong performance by newly launched growth drivers (net sales growth at Act rates): EVENITY ® +140%, FINTEPLA ® +94%, BIMZELX ® +323%. RYSTIGGO ® with € 19 million since July, ZILBRYSQ ® launched globally since Q1 2024 Underlying profitability (adj. EBITDA 2 ) was € 1.35...

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive PR Newswire ATLANTA, Jan. 3, 2024 ZILBRYSQ ® (zilucoplan) is now commercially available by prescription in the United States and dispensed by UCB's selected exclusive specialty pharmacy PANTHERx ® Rare Pharmacy. ZILBRYSQ is FDA-approved as the first and only self-administered C5 complement...

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting PR Newswire ATLANTA, Dec. 2, 2023 Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months 1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic...

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting PR Newswire ATLANTA, Dec. 1, 2023 UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and demographic studies in epilepsy Presentations showcase diversity, potential and momentum of UCB's epilepsy and rare syndromes portfolio, including important fenfluramine and brivaracetam data Broad data...

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire ATLANTA, Nov. 14, 2023 BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States BIMZELX is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis BIMZELX Navigate™, a personalized patient support system, is available to eligible patients to provide support...

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) PR Newswire ATLANTA, Nov. 11, 2023 A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels achieved low disease activity at Week 104 1 CIMZIA maintained drug concentrations and achieved Low Disease Activity regardless of RF levels in...